Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tg Therapeutics (TGTX)

Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Tg Therapeutics 3020 CARRINGTON MILL BLVD SUITE 475 MORRISVILLE NC 27560 USA

www.tgtherapeutics.com Employees: 338 P: 877-575-8489

Sector:

Medical

Description:

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.

Key Statistics

Overview:

Market Capitalization, $K 4,648,464
Enterprise Value, $K 4,713,004
Shares Outstanding, K 158,759
Annual Sales, $ 329,000 K
Annual Net Income, $ 23,380 K
Last Quarter Sales, $ 161,710 K
Last Quarter Net Income, $ 390,900 K
EBIT, $ 102,780 K
EBITDA, $ 98,070 K
60-Month Beta 1.86
% of Insider Shareholders 10.64%
% of Institutional Shareholders 58.58%
Float, K 141,867
% Float 89.36%
Short Interest 25,111
Short Float 15.82%
Short Volume Ratio 0.36

Growth:

1-Year Return 8.36%
3-Year Return 122.60%
5-Year Return -38.86%
5-Year Revenue Growth 219,233.33%
5-Year Earnings Growth 108.20%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 2.43 on 11/03/25
Next Earnings Date 03/02/26
Earnings Per Share ttm 2.78
EPS Growth vs. Prev Qtr 1,329.41%
EPS Growth vs. Prev Year 12,050.00%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-56 on 04/27/12

TGTX Ratios

Ratio
Price/Earnings ttm 10.72
Price/Earnings forward 15.33
Price/Earnings to Growth N/A
Return-on-Equity % 133.25%
Return-on-Assets % 60.43%
Profit Margin % 7.11%
Debt/Equity 0.40
Price/Sales 9.22
Price/Cash Flow 248.49
Price/Book 7.79
Book Value/Share 3.83
Interest Coverage 2.06
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar